	US 11,939,386 B2
	AXL-targeting antibody, antibody-drug conjugate, preparation method therefor, and use thereof
Ke Yu, Shanghai (CN); Jingkang Shen, Shanghai (CN); Tao Meng, Shanghai (CN); Jinpeng Pei, Shanghai (CN); Lanping Ma, Shanghai (CN); Xin Wang, Shanghai (CN); Rui Jin, Shanghai (CN); Zhiyan Du, Shanghai (CN); Lin Chen, Shanghai (CN); Ting Yu, Shanghai (CN); and Yongliang Zhang, Shanghai (CN)
Assigned to Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai (CN)
Appl. No. 17/055,499
Filed by FUDAN UNIVERSITY, Shanghai (CN); and SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, Shanghai (CN)
PCT Filed May 10, 2019, PCT No. PCT/CN2019/086475 § 371(c)(1), (2) Date Nov. 13, 2020, PCT Pub. No. WO2019/218944, PCT Pub. Date Nov. 21, 2019.
Claims priority of application No. 201810464287.1 (CN), filed on May 15, 2018.
Prior Publication US 2021/0214447 A1, Jul. 15, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C12N 5/078 (2010.01)

CPC C07K 16/2863 (2013.01) [A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6817 (2017.08); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C12N 5/0634 (2013.01); A61K 2039/505 (2013.01)]

15 Claims

1. An antibody, which binds to AXL, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain has a heavy chain variable region comprising the following three complementarity determining regions or CDRs:

CDR1 as shown in SEQ ID NO. 1,

CDR2 as shown in SEQ ID NO. 2, and

CDR3 as shown in SEQ ID NO. 3; and

the light chain has a light chain variable region comprising the following three complementarity determining regions or CDRs:

CDR1′ as shown in SEQ ID NO. 4,

CDR2′ as shown in SEQ ID NO. 5, and

CDR3′ as shown in SEQ ID NO. 6;

or,

the heavy chain has a heavy chain variable region comprising the following three complementarity determining regions or CDRs:

CDR1 as shown in SEQ ID NO. 9,

CDR2 as shown in SEQ ID NO. 10, and

CDR3 as shown in SEQ ID NO. 11; and

the light chain has a light chain variable region comprising the following three complementarity determining regions or CDRs:

CDR1′ as shown in SEQ ID NO. 12,

CDR2′ as shown in SEQ ID NO. 13, and

CDR3′ as shown in SEQ ID NO. 14;

or,

the heavy chain has a heavy chain variable region comprising the following three complementarity determining regions or CDRs:

CDR1 as shown in SEQ ID NO. 17,

CDR2 as shown in SEQ ID NO. 18, and

CDR3 as shown in SEQ ID NO. 19; and

the light chain has a light chain variable region comprising the following three complementarity determining regions or CDRs:

CDR1′ as shown in SEQ ID NO. 20,

CDR2′ as shown in SEQ ID NO. 21, and

CDR3′ as shown in SEQ ID NO. 22.